OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
Peng Ding, Z. Ma, Yizeng Fan, et al.
Genes & Diseases (2022) Vol. 10, Iss. 3, pp. 848-863
Open Access | Times Cited: 15
Peng Ding, Z. Ma, Yizeng Fan, et al.
Genes & Diseases (2022) Vol. 10, Iss. 3, pp. 848-863
Open Access | Times Cited: 15
Showing 15 citing articles:
Unleashing the power of immune checkpoints: Post-translational modification of novel molecules and clinical applications
Jie Wang, Yian Wang, Xianjie Jiang, et al.
Cancer Letters (2024) Vol. 588, pp. 216758-216758
Closed Access | Times Cited: 14
Jie Wang, Yian Wang, Xianjie Jiang, et al.
Cancer Letters (2024) Vol. 588, pp. 216758-216758
Closed Access | Times Cited: 14
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
Feng Zhang, Ruiya Jiang, Shishi Sun, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116267-116267
Closed Access | Times Cited: 6
Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma
Min Shi, Na Shen, Xiangyu Liu, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Min Shi, Na Shen, Xiangyu Liu, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
A comprehensive analysis of deubiquitinase USP20 on prognosis and immunity in pan‐cancer
Ting Wang, Yibing Bai, Yi Dong, et al.
The FASEB Journal (2025) Vol. 39, Iss. 8
Closed Access
Ting Wang, Yibing Bai, Yi Dong, et al.
The FASEB Journal (2025) Vol. 39, Iss. 8
Closed Access
Cuncun Zhang, Ning-Ning Sun, Qing-Ze Fei, et al.
Cancer Science (2024) Vol. 115, Iss. 8, pp. 2515-2527
Open Access | Times Cited: 3
FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies
Wanqing Wang, Kaipeng Jiang, Xue Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Wanqing Wang, Kaipeng Jiang, Xue Liu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy
Soon-Bin Kim, Soonjae Hwang, Ji-Young Cha, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2939-2939
Open Access | Times Cited: 2
Soon-Bin Kim, Soonjae Hwang, Ji-Young Cha, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2939-2939
Open Access | Times Cited: 2
Bio-Pathological Functions of Posttranslational Modifications of Histological Biomarkers in Breast Cancer
Anca-Narcisa Neagu, Claudiu-Laurentiu Josan, Taniya Jayaweera, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4156-4156
Open Access | Times Cited: 2
Anca-Narcisa Neagu, Claudiu-Laurentiu Josan, Taniya Jayaweera, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4156-4156
Open Access | Times Cited: 2
Novel Lactams as CBL-B Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 7, pp. 897-898
Open Access | Times Cited: 6
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 7, pp. 897-898
Open Access | Times Cited: 6
LDHB Mediates Histone Lactylation to Activate PD-L1 and Promote Ovarian Cancer Immune Escape
Xuemei Hu, Zhenqiang Huang, Lingyun Li
Cancer Investigation (2024) Vol. 43, Iss. 1, pp. 70-79
Open Access | Times Cited: 1
Xuemei Hu, Zhenqiang Huang, Lingyun Li
Cancer Investigation (2024) Vol. 43, Iss. 1, pp. 70-79
Open Access | Times Cited: 1
Novel Lactams as Cbl-b Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 10, pp. 1556-1557
Open Access | Times Cited: 5
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 10, pp. 1556-1557
Open Access | Times Cited: 5
Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy
Wenhui Xu, Jinghong Ye, Zhen‐Dong Cao, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e32357-e32357
Open Access
Wenhui Xu, Jinghong Ye, Zhen‐Dong Cao, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e32357-e32357
Open Access
The Dysregulation of Deubiquitinases in Gastric Cancer Progression
Zifan Xu, Zi Lei, Shilan Peng, et al.
(2024)
Closed Access
Zifan Xu, Zi Lei, Shilan Peng, et al.
(2024)
Closed Access
Dysregulation of deubiquitinases in gastric cancer progression
Zifan Xu, Zi Lei, Shilan Peng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Zifan Xu, Zi Lei, Shilan Peng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial–mesenchymal transition
Danxiang Chen, Jing Jiang, Wei Zhang, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access
Danxiang Chen, Jing Jiang, Wei Zhang, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access
Caryophylli Cortex Suppress PD-L1 Expression in Cancer Cells and Potentiates Anti-Tumor Immunity in a Humanized PD-1/PD-L1 Knock-In MC-38 Colon Cancer Mouse Model
Aeyung Kim, Eun‐Ji Lee, Jung Ho Han, et al.
Nutrients (2024) Vol. 16, Iss. 24, pp. 4415-4415
Open Access
Aeyung Kim, Eun‐Ji Lee, Jung Ho Han, et al.
Nutrients (2024) Vol. 16, Iss. 24, pp. 4415-4415
Open Access
